Oncovista Innovative Therapies, Inc. Announces The Initiation Of Clinical Development Of Adnagen's Breast Cancer Circulating Tumor Cells Diagnostic Technology In Women With High-Risk Locally Advanced

SAN ANTONIO -- OncoVista Innovative Therapies, Inc. and AdnaGen Ag announced that The University of Texas M. D. Anderson Cancer Center will collaborate on clinical studies of AdnaGen's molecular based CTC technology in Women with High-Risk Locally Advanced Breast Cancer (LABC) that have completed Neoadjuvant and Local Therapy. "M. D. Anderson is dedicated to helping develop novel approaches that may improve the prognosis of patients with malignant diseases," said Dr. Massimo Cristofanilli, Associate Professor of Medicine and the Director of the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic. Dr. Cristofanilli added: "We are dedicated to improving the prognosis of patients with advanced breast canc...